
    
      This is a multicenter, randomized, Phase Ib/IIb, open label study to evaluate the efficacy
      and tolerability of gefitinib in combination with olaparib (AZD2281) versus gefitinib alone,
      in patients with Epidermal Growth Factor Receptor (EGFR) mutation positive advanced
      non-small-cell lung cancer The study will be split into 2 parts: an open label Phase I dose
      escalation part and a randomized controlled, open label Phase II part.
    
  